Is Privia Health Group, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, significantly higher than peers like Globe Life, Inc. with a P/E of 11.82 and Primerica, Inc. at 12.59, indicating a stark contrast in valuation. Additionally, the EV to EBITDA ratio is 82.17, which also suggests a premium compared to the industry.
In terms of performance, Privia Health has shown a strong return of 48.68% over the past year, compared to the S&P 500's 16.90%, highlighting its relative strength in the market despite its high valuation ratios. The company's ROCE of 11.11% and ROE of 2.37% further illustrate its operational efficiency, although these figures still reflect a need for improvement relative to its peers. Overall, while Privia Health Group, Inc. is currently fairly valued, its high valuation ratios compared to peers suggest caution for potential investors.